BOSTON, June 13,
2023 /PRNewswire/ -- NeuroBo Pharmaceuticals,
Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on
a quest to transform cardiometabolic diseases, today announced that
data on DA-1726, a novel oxyntomodulin (OXM) analogue functioning
as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor
(GCGR) dual agonist, was accepted for one ePoster theater
discussion and two general poster presentations at the American
Diabetes Association 83rd Scientific Sessions, being
held June 23-26, 2023 at the
San Diego Convention Center in
San Diego, CA and virtually.
"Having two posters selected, including one for an ePoster
theater discussion, at such a prestigious scientific meeting, is a
testament to the scientific community's view of the strength of the
preclinical data generated, thus far, for DA-1726," stated
Joe Hooker, Interim President and
Chief Executive Officer of NeuroBo. "As previously announced,
we intend to advance DA-1726, a long acting OXM analog that binds
and activates both glucagon-like peptide-1 (GLP-1) and glucagon
receptors, leading to weight loss through reduced appetite and
increased energy expenditure, through the IND process during the
second half of this year. If accepted by the U.S. Food and Drug
Administration, we plan to initiate a phase 1a safety study in the
first half of 2024, with a data readout expected in the second half
of 2024."
ePoster Theater
Presentation:
Yuna Chae,
DA-1726 Project Manager, Dong-A ST Research Center, will present a
digital poster and high-level overview of the poster findings in an
open discussion with a session moderator.
Abstract Title: Differentiated Metabolic Effects
of DA-1726, a Balanced GLP1R/GCGR Dual
Agonist
Presenter: Yuna
Chae, DA-1726 Project Manager, Dong-A ST Research Center
Session: ePoster Theater
Date and Time: Sunday, June 25,
2023, 12:10 PM – 12:20 PM PDT
Location: Exhibit Hall (ePoster Theater A)
Poster: 1668
Poster Presentations:
Abstract Title: A
Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior
to Semaglutide in Diet-Induced Obese Rats
Authors:
Tae-Hyoung Kim, Il-Hun Jung,
Kyumin Kim, Hyung Heon Kim, Mi-Kyung
Kim, Yuna Chae
Presenter: Tae-hyoung
Kim, Dong-A ST Research Center
Session: General Poster Session
Date and Time: Monday, June 26,
2023, 11:30 AM - 12:30 PM
PDT
Location: Poster Halls B-C
Poster: 1676
Abstract Title: Differentiated Metabolic Effects
of DA-1726, a Balanced GLP1R/GCGR Dual
Agonist
Authors: Il-Hun Jung, Tae-Hyoung Kim, Su Jin
Lee, Hyung Heon Kim,
Mi-Kyung Kim, Yuna Chae
Presenter: Yuna Chae, Dong-A ST Research
Center
Session: General Poster Session
Date and Time: Monday, June 26,
2023, 11:30 AM - 12:30 PM
PDT
Location: Poster Halls B-C
Poster: 1668
Copies of abstracts will also be available on the NeuroBo
Pharmaceuticals website
at https://www.neurobopharma.com/presentations following
completion of the live presentation.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals,
Inc. is a clinical-stage biotechnology company on a quest to
transform cardiometabolic diseases. The company is currently
developing DA-1241 for the treatment of Non-Alcoholic
Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM), and is
developing DA-1726 for the treatment of obesity. DA-1241 is a novel
G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the
release of key gut peptides GLP-1, GIP, and PYY. In preclinical
studies, DA-1241 demonstrated positive effect on liver
inflammation, lipid metabolism, weight loss, and glucose
metabolism, reducing hepatic steatosis, hepatic inflammation, and
liver fibrosis, while also improving glucose control. DA-1726 is a
novel oxyntomodulin (OXM) analogue that acts as a glucagon-like
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual
agonist. OXM is a naturally-occurring gut hormone that activates
GLP1R and GCGR, thereby decreasing food intake while increasing
energy expenditure, thus potentially resulting in superior body
weight loss compared to selective GLP1R agonists.
For more information, please
visit www.neurobopharma.com.
Forward Looking Statements
Certain statements in this
release may be considered forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including without limitation, statements about the closing of the
offering of securities. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risks associated with our ability to execute on our commercial
strategy, the timeline for regulatory submissions, regulatory steps
and potential regulatory approval of our current and future product
candidates, the ability to realize the benefits of the license
agreement with Dong-A ST Co. Ltd., including the impact on future
financial and operating results of NeuroBo; the ability to
integrate the new product candidates into NeuroBo's business in a
timely and cost-efficient manner; the cooperation of our contract
manufacturers, clinical study partners and others involved in the
development of our current and future product candidates; our
ability to initiate and complete clinical trials on a timely basis;
our ability to recruit subjects for our clinical trials; costs
related to the license agreement, known and unknown, including
costs of any litigation or regulatory actions relating to the
license agreement; changes in applicable laws or regulations;
effects of changes to NeuroBo's stock price on the terms of the
license agreement and any future fundraising; and other risks and
uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
NeuroBo does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-announces-acceptance-of-two-general-posters-and-one-eposter-theater-discussion-of-its-novel-glp1r-and-gcgr-dual-agonist-da-1726-at-the-american-diabetes-association-83rd-scientific-sessions-301848760.html
SOURCE NeuroBo Pharmaceuticals, Inc.